Syndex Bio’s mcPCR opens new path for early disease detection
Syndex Bio unveiled mcPCR, a PCR-based method that copies DNA together with methylation patterns. The company raised $15.5M in seed funding and positions the platform for earlier cancer detection and higher-fidelity epigenetic clocks.
Why it mattersMcPCR preserves methylation signals for epigenetic clocks; investors should re-evaluate diagnostics exposure after $15.5M seed funding.
Entities Mentioned
Syndex Bio